natgillin/translations-raw huggingface dataset:
Treatment-emergent positive bivalirudin antibodies are rare and have not been associated with clinical evidence of allergic or anaphylactic reactions. 
Pozitivna protitelesa proti bivalirudinu zaradi zdravljenja so redka in niso povezana s kliničnimi dokazi alergijske ali anafilaktične reakcije.
Pharmacokinetics have been evaluated in elderly patients as part of a renal pharmacokinetic study. 
Farmakokinetika je bila pri starejših ovrednotena kot del ledvične farmakokinetične študije.
What Angiox is and what it is used for What you need to know before you use Angiox 
Kaj je zdravilo Angiox in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Angiox
• severe uncontrolled hypertension 
• resno nenadzorovano hipertenzijo
these medicines may increase the risk of side effects such as bleeding when given at the same time as Angiox. 
Ta zdravila lahko povečajo tveganje za pojav neželenih učinkov, kot je krvavitev, če se jih daje skupaj z zdravilom Angiox.
In a clinical trial of 110 paediatric patients (neonates to <16 years of age) undergoing percutaneous intravascular procedures, the safety, pharmacokinetic and pharmacodynamic profile of bivalirudin was evaluated [TMC-BIV-07-01]. 
V kliničnem preskušanju s 110 pediatričnimi bolniki (novorojenčki do < 16 let starosti) z načrtovanimi perkutanimi intravaskularnimi postopki so ocenili varnost, farmakokinetiko in farmakodinamični profil bivalirudina [TMC-BIV-07-01].
The slide deck will contain the following key information: 
Predstavitev z diapozitivi bo vsebovala spodnje ključne informacije:
The arterial sheath can be removed 2 hours after discontinuation of the bivalirudin infusion without anticoagulation monitoring. 
Arterijsko iglo lahko odstranite dve uri po končani infuziji bivalirudina brez nadaljnjega nadzora antikoagulacije.
The most frequent event was a haematoma <5 cm at puncture site. 
Najpogostejši neželeni učinek je bil hematom < 5 cm na mestu vboda.
• if you are having radiation treatment in the vessels that supply blood to the heart (treatment called beta or gamma brachytherapy). 
• če se zdravite z obsevanjem žil, ki dostavljajo kri do srca (zdravljenje se imenuje beta ali gama brahiterapija)
WHAT ANGIOX IS AND WHAT IT IS USED FOR 
Kaj je zdravilo Angiox in za kaj ga uporabljamo
Minor bleeding was defined as any observed bleeding event that did not meet the criteria as major. 
Manjšo krvavitev so opredelili kot vsako opaženo krvavitev, ki ni izpolnjevala kriterijev za večjo krvavitev.
This dosing pattern was associated with increased in-hospital ischaemic events (MACE). 
Ta vzorec odmerjanja je bil povezan z zvečanjem bolnišničnih ishemičnih dogodkov (MACE).
In clinical studies bivalirudin has been shown to provide adequate anticoagulation during PCI procedures. 
Klinične študije kažejo, da bivalirudin omogoča zadostno antikoagulacijo med postopkom PCI.
Bivalirudin is rapidly distributed between plasma and extracellular fluid. 
Bivalirudin se hitro porazdeli med plazmo in ekstracelularno tekočino.
The doctor will check the solution and will discard it, if it contains particles or is discoloured. 
Zdravnik bo raztopino pregledal in jo zavrgel, če bo vsebovala delce ali če bo barva spremenjena..
The 30-day results based on quadruple and triple endpoints from a randomized, double-blind trial of over 6,000 patients undergoing PCI (REPLACE-2) are shown in Table 5. 
30-dnevni rezultati na osnovi štirikratnih in trikratnih opazovanih dogodkov, v randomiziranem, dvojno slepem preizkušanju s preko 6.000 bolniki med PCI (REPLACE-2) so prikazani v preglednici 5.
Bivalirudin remains active and is not neutralised by products of the platelet release reaction. 
Bivalirudin ostane aktiven in ga ne nevtralizirajo produkti sprostitvene reakcije krvnih ploščic.
They may begin with limited symptoms such as itching, redness of the skin, rash or small bumps on the skin. 
Lahko se začnejo z določenimi simptomi, kot so srbenje, rdečina kože, izpuščaj ali majhne bulice na koži.
Major bleeding in the HORIZONS study was also defined using the ACUITY scale. 
Večja krvavitev v študiji HORIZON je bila prav tako opredeljena z uporabo lestvice ACUITY.
Clearance is reduced by approximately 20% in patients with moderate or severe renal impairment, and 80% in dialysis-dependent patients (Table 8). 
Očistek se pri bolnikih z zmerno ali hudo ledvično okvaro zmanjša za približno 20 %, pri dializnih bolnikih pa za 80 % (preglednica 8).
OUTER CARTON (pack of 10 vials) 
ŠKATLA (pakiranje z 10 vialami).
Do not administer intramuscularly. 
Zdravila ne dajajte intramuskularno.
In the elderly, if their kidney function is decreased, the dose may need to be reduced. 
Pri starejših ljudeh, ki imajo zmanjšano delovanje ledvic, bo morda treba odmerek zmanjšati.
As Angiox is a hospital only medicine, storage of Angiox is the responsibility of healthcare professionals. 
Ker se zdravilo Angiox uporablja samo v bolnišnicah, je za shranjevanje zdravila Angiox odgovorno zdravstveno osebje.
Angiox contains a substance called bivalirudin which is an antithrombotic medicine. 
Zdravilo Angiox vsebuje snov, ki se imenuje bivalirudin, in je antitrombotsko zdravilo.
Occasionally, reactions can be more severe with throat itching, throat tightening, swelling of the eyes, face, tongue or lips, high pitched whistling during inhaling (stridor), difficulty breathing or exhaling (wheezes). 
Občasno so lahko reakcije hujše in vključujejo srbenje v grlu, stiskanje v grlu, otekanje oči, obraza, jezika in ustnic, visoki zvoki pri vdihavanju (stridor), oteženo dihanje ali izdihavanje (piskanje v pljučih).
It is unknown whether bivalirudin is excreted in human milk. 
Ni jasno, ali se bivalirudin izloča v materino mleko.
A population pharmacokinetic/pharmacodynamic analysis, and an Exposure and Adverse Event Assessment Model based on the data from this study determined that in paediatric patients, use of the adult dosing with plasma levels similar to that achieved in adults was associated with lower levels of thrombotic events with no impact on bleeding events (see section 4.2). 
Analiza farmakokinetike/farmakodinamike populacije in model izpostavljenosti in ocene neželenih dogodkov na podlagi podatkov te študije sta pokazala, da je bila pri pediatričnih bolnikih uporaba odmerka za odrasle z ravnmi v plazmi, podobnimi tistim, ki so bile dosežene pri odraslih, povezana z manjšo ravnjo trombotičnih dogodkov in ni imela vpliva na dogodke krvavitve (glejte poglavje 4.2).
Similar reductions in bleeding were observed in patients who were switched to bivalirudin from heparin-based therapies (N = 2,078). 
Podobna znižanja števila primerov krvavitev je bilo opaziti tudi pri bolnikih, ki so prešli z zdravljenja na osnovi heparina na bivalirudin (N = 2.078).
In the event of major bleeding, treatment with bivalirudin should be immediately discontinued. 
V primeru večje krvavitve nemudoma prekinite zdravljenje z bivalirudinom.
Angiox should be administered with acetylsalicylic acid and clopidogrel. 
Zdravilo Angiox je treba dajati z acetilsalicilno kislino in klopidogrelom.
Angiox is not intended for intramuscular use. 
Angiox ni namenjen intramuskularni uporabi.
Table 9 summarises compatible and incompatible concentrations of these compounds. 
V preglednici 9 je prikazan povzetek združljivih in nezdružljivih koncentracij omenjenih učinkovin.
The primary analysis and results for ACUITY at 30-days and 1 year for the overall (ITT) population and for the patients that received acetylsalicylic acid and clopidogrel as per protocol (pre-angiography or pre-PCI) are shown in Tables 3 and 4. 
Primarna analiza in rezultati študije ACUITY po 30 dneh in 1 letu za celotno vključeno populacijo (ITT) in za bolnike, ki so prejemali acetilsalicilno kislino ter klopidogrel v skladu s protokolom (pred angiografijo ali pred PCI), so prikazani v preglednicah 3 in 4.
In REPLACE-2, bleeding data were collected separately from adverse events. 
V REPLACE-2 so bili podatki o krvavitvah zbrani ločeno od neželenih dogodkov.
o while you are in hospital: tell the doctor or nurseo after you've left hospital: first seek advice from your doctor. 
o ko ste v bolnišnici: takoj obvestite zdravnika ali medicinsko sestro o ko zapustite bolnišnico: najprej poiščite nasvet svojega zdravnika.
Uncommonly (may affect up to 1 in 100 people) the number of blood platelets may be low which can worsen any bleeding. 
Občasno (pojavijo se lahko pri največ 1 od 100 bolnikov) je lahko število krvnih ploščic majhno, kar lahko poslabša krvavitev.
To ensure appropriate administration of bivalirudin, the completely dissolved, reconstituted and diluted product should be thoroughly mixed prior to administration (see section 6.6). 
Da bi zagotovili ustrezno dajanje bivalirudina, je potrebno pred dajanjem popolnoma raztopljeno, rekonstituirano in razredčeno zdravilo temeljito zmešati (glejte poglavje 6.6).
From the knowledge of their mechanism of action, combined use of anti-coagulant medicinal products (heparin, warfarin, thrombolytics or antiplatelet agents) can be expected to increase the risk of bleeding. 
Ker poznamo njihov mehanizem delovanja, lahko pri skupni uporabi antikoagulantov (heparin, varfarin, trombolitiki ali zaviralci krvnih ploščic) pričakujemo povečano tveganje za krvavitve.
Patients with renal impairment should be carefully monitored for clinical signs of bleeding during PCI, as clearance of bivalirudin is reduced in these patients (see section 5.2) 
Pri bolnikih z okvaro ledvic je treba skrbno spremljati klinične znake krvavitve med PCI, saj je očistek bivalirudina pri teh bolnikih zmanjšan (glejte poglavje 5.2).
Bleeding is more likely to occur when Angiox is used in combination with other anticoagulant or antithrombotic medicines (see section 2 ‘Taking other medicines'). 
Pojav krvavitve je bolj verjeten, kadar zdravilo Angiox uporabljate v kombinaciji z drugimi antikoagulacijskimi ali antitrombotičnimi zdravili (glejte poglavje 2 "Druga zdravila in zdravilo Angiox ").
In STEMI patients undergoing primary PCI, standard pre-hospital adjunctive therapy should include clopidogrel and may include the early administration of UFH (See section 5.1). 
Pri bolnikih s STEMI, pri katerih se bo izvedla primarna PCI, mora standardna predhospitalizacijska terapija vključevati klopidogrel, lahko pa vključuje tudi zgodnjo uporabo UFH (glejte razdelek 5.1).
Patients in Arms A and B were also randomised to receive a GP IIb/IIIa inhibitor either upfront at the time of randomization (prior to angiography) or at the time of PCI. 
Bolniki v krakih A in B so bili randomizirani tudi glede tega, ali so prejeli inhibitor GP IIIb/IIIa vnaprej, tj. ob času randomizacije (pred angiografijo), ali v času PCI.
• Angina or chest pain 
• angina pektoris ali bolečine v prsih
Thrombin plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently crosslinked framework that stabilises the thrombus. 
Trombin ima osrednjo vlogo pri trombotskem procesu, saj fibrinogen cepi na monomere fibrina in aktivira faktor XIII v faktor XIIIa, kar fibrinu omogoča, da razvije kovalentno premreženo ogrodje, ki stabilizira trombus.
Caution should be exercised in patients previously treated with lepirudin who had developed lepirudin antibodies. 
Bodite pozorni pri bolnikih, ki so bili predhodno zdravljeni z lepirudinom in so razvili protitelesa proti lepirudinu.
Unexplained decreases in haematocrit, haemoglobin or blood pressure may indicate haemorrhage. 
Nepojasnjeno znižanje hematokrita, hemoglobina ali krvnega tlaka lahko kaže na krvavitev.
Driving and using machines the effects of this medicine are known to be short-term. 
Znano je, da so učinki tega zdravila kratkotrajni.
• subacute bacterial endocarditis 
• subakutnim bakterijskim endokarditisom;
The following data is based on a clinical study of bivalirudin in 6,000 patients undergoing PCI, half of whom were treated with bivalirudin (REPLACE-2). 
Naslednji podatki temeljijo na klinični študiji z bivalirudinom pri 6.000 bolnikih med PCI, od katerih je bila polovica zdravljenih z bivalirudinom (REPLACE-2).
Hälsa Pharma GmbH Nikolaus Dürkopp-Str. 4A 33602 Bielefeld GERMANY 
Hälsa Pharma GmbH Nikolaus Dürkopp-Str. 4A 33602 Bielefeld Nemčija
WHAT YOU NEED TO KNOW BEFORE YOU USE ANGIOX 
Kaj morate vedeti, preden boste uporabili zdravilo Angiox
The HORIZONS trial was a prospective, dual arm, single blind, randomised, multi-centre trial to establish the safety and efficacy of bivalirudin in patients with STEMI undergoing a primary PCI strategy with stent implantation with either a slow release paclitaxel-eluding stent (TAXUS™) or an otherwise identical uncoated bare metal stent (Express2™). 
Preskušanje HORIZONS je bilo prospektivno, dvojno krako, enojno slepo, randomizirano preskušanje, ki je preverilo varnost in učinkovitost bivalirudina pri bolnikih s STEMI, pri katerih se je izvedla primarna strategija PCI s stenti, ki počasi sproščajo paklitaksel (TAXUS™) ali identičnimi metalnimi stenti brez filma (Express2™).
Mannitol, sodium hydroxide 2% 
Manitol, 2 % natrijev hidroksid.
Rarely this may require surgery to repair the blood vessel in the groin (fistula, pseudoaneurysm) (may affect up to 1 in 1,000 people). 
Redko je morda potrebna operacija za popravilo krvnih žil v dimljah (fistula, psevdoanevrizem) (pojavijo se lahko pri največ 1 od 1.000 bolnikov).
The most common, (may affect up to 1 in 10 people) serious side effect of treatment with Angiox, is major bleeding which could occur anywhere inside the body (e.g. stomach, digestive system (including vomiting blood or passing blood with the stools), abdomen, lungs, groin, bladder, heart, eye, ear, nose or brain). 
Najpogostejši (pojavijo se lahko pri več kot 1 od 10 bolnikov) resni neželeni učinek zdravljenja z zdravilom Angiox je obsežna krvavitev, ki se lahko pojavi kjer koli v telesu (npr. želodcu, prebavnem sistemu (vključno z bruhanjem in krvjo v blatu), trebuhu, pljučih, dimljah, sečnem mehurju, očeh, ušesih, nosu ali možganih).
Additional anti-platelet therapy utilised in the study included acetylsalicylic acid and clopidogrel. 
Dodatna antitrombocitna terapija, ki so jo uporabljali v študiji, je vključevala uporabo acetilsalicilne kisline in klopidogrela.
Normal renal function (≥ 90ml/min) Mild renal impairment (60-89 ml/min) Moderate renal impairment (30-59 ml/min) Severe renal impairment (10-29 ml/min) Dialysis dependent patients (off-dialysis) 
Normalna ledvična funkcija (≥90 ml/min) Blaga ledvična okvara (60 -89 ml/min) Zmerna ledvična okvara (30 -59 ml/min) Huda ledvična okvara (10 -29 ml/min) Dializni bolniki (ne med dializo)
There are no or limited data from the use of bivalirudin in pregnant women. 
Ni podatkov o uporabi bivalirudina pri nosečnicah oziroma so ti omejeni.
The intravenous infusion may continue at this dose for up to 4 hours after the PCI and for STEMI patients (those with a severe type of heart attack) it should continue at this dose for up to 4 hours. 
Intravensko infundiranje tega odmerka se lahko nadaljuje največ 4 ure po PCI, medtem ko je pri bolnikih s STEMI (tistih s hudim srčnim infarktom) treba nadaljevati s tem odmerkom največ 4 ure.
Patients can be started on Angiox 30 minutes after discontinuation of unfractionated heparin given intravenously, or 8 hours after discontinuation of low molecular weight heparin given subcutaneously. 
Bolniki lahko začnejo prejemati zdravilo Angiox 30 minut po prekinitvi intravenskega dajanja nefrakcioniranega heparina ali 8 ur po prekinitvi subkutanega dajanja heparina z nizkomolekularno maso.
The dosing cards will contain the following key information: 
Kartice za odmerjanje vsebujejo spodnje ključne informacije:
The bolus dose should be administered by a rapid intravenous push to ensure that the entire bolus reaches the patient before the start of the procedure. 
Bolusni odmerek je treba dati s hitrim intravenskim vbrizgom, da celotni bolusni odmerek doseže bolnika pred začetkom postopka.
Although most bleeding associated with bivalirudin occurs at the site of arterial puncture in patients undergoing PCI, haemorrhage can occur at any site during therapy. 
Čeprav do krvavitve zaradi bivalirudina večinoma pride na mestu arterijske punktacije pri bolnikih med PCI, lahko med terapijo pride do krvavitve na kateremkoli mestu.
Adverse reactions for bivalirudin from HORIZONS, ACUITY, REPLACE-2 trials and post-marketing experience are listed by system organ class in Table 1. 
Neželeni učinki bivalirudina iz preskušanj HORIZONS, ACUITY, REPLACE-2 in izkušenj v obdobju trženja so navedeni v preglednici 1 po organskih sistemih.
This may, rarely, result in a stroke or be fatal. 
To lahko v redkih primerih privede do možganske kapi ali smrti.
A total of 356 (7.7%) of patients randomised to Arm C also received a GP IIb/IIIa inhibitor. 
Skupaj 356 (7,7 %) bolnikov, ki so bili randomizirani v krak C, je prav tako prejelo inhibitor GP IIb/IIIa.
• Tabulated information on dosing by body weight of patient. 
• Informacije o odmerjanju glede na telesno maso bolnika v preglednicah.
Angiox should be administered by a physician experienced in either acute coronary care or in coronary intervention procedures. 
Zdravilo Angiox naj daje zdravnik, ki ima izkušnje bodisi z zdravljenjem akutnega koronarnega sindroma ali s postopki koronarne intervencije.
Pharmacotherapeutic group: antithrombotic agents, Direct thrombin inhibitors, ATC code: B01AE06. 
5.1 Farmakodinamične lastnosti Farmakoterapevtska skupina: antitrombotiki, direktni zaviralci trombina, oznaka ATC: B01AE06.
Angiox can be used in conjunction with a GP IIb/IIIa inhibitor. 
Zdravilo Angiox lahko uporabljate v kombinaciji z zaviralcem GP IIb/IIIa.
• The most frequent serious and fatal adverse reactions are major haemorrhage (access site and non access-site bleeding, including intracranial haemorrhage) and hypersensitivity, including anaphylactic shock. 
• Najpogostejši resni in smrtni neželeni učinki so večje krvavitve (krvavitev na mestu aplikacije in izven mesta aplikacije, vključno z možgansko krvavitvijo) in preobčutljivost, vključno z anafilaktičnim šokom.
Thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release. 
Trombin aktivira tudi faktorja V in VIII ter s tem pospeši nadaljnjo tvorbo trombina in aktivira krvne ploščice, s čimer stimulira agregacijo in sprostitev granul.
In cases of overdose, treatment with bivalirudin should be immediately discontinued and the patient monitored closely for signs of bleeding. 
V primeru prekomernega odmerjanja nemudoma prekinite zdravljenje z bivalirudinom in temeljito preverite, ali bolnik kaže znake krvavitve.
TIMI major bleeding was defined as intracranial bleeding or a decrease in haemoglobin concentration ≥5 g/dl. 
Večja krvavitev TIMI je bila opredeljena kot intrakranialna krvavitev ali kot zmanjšanje koncentracije hemoglobina za ≥ 5 g/dl.
Angiox is available in cartons containing 10 vials. 
Zdravilo Angiox je na razpolago v škatlah, ki vsebujejo 10 vial.
• active bleeding or increased risk of bleeding because of haemostasis disorders and/or irreversible coagulation disorders 
• aktivno krvavitvijo ali povečanim tveganjem za krvavitve zaradi motenj hemostaze ali trajnih
- The active substance is bivalirudin. 
- Zdravilna učinkovina je bivalirudin.
The pharmacokinetics of bivalirudin have not been studied in patients with hepatic impairment but are not expected to be altered because bivalirudin is not metabolized by liver enzymes such as cytochrome P-450 isozymes. 
Farmakokinetika bivalirudina ni bila preučena pri bolnikih z okvarjenimi jetri, vendar se verjetno ne bo spremenila, ker bivalirudina ne presnavljajo jetrni encimi, kot so izoencimi citokroma P-450.
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH 
A. IZDELOVALEC (IZDELKOVALCI) , ODGOVOREN
Angiox is supplied as a lyophilised powder in 10 ml single use glass vials (Type 1) closed with a butyl rubber stopper and sealed with a crimped aluminum seal. 
Zdravilo Angiox je dobavljeno kot liofiliziran prašek v 10 ml steklenih vialah (Tip 1) za enkratno uporabo, zaprtih z butilnim gumijastim zamaškom in nabranim aluminijastim zamaškom.
Angiox is intended for intravenous use. 
Zdravilo Angiox je namenjeno intravenski uporabi.
The safety and efficacy of a bolus dose of bivalirudin without the subsequent infusion has not been evaluated and is not recommended even if a short PCI procedure is planned. 
Varnost in učinkovitost bolusnega odmerka bivalirudina brez poznejše infuzije niso ocenjevali in ni priporočen, tudi če se načrtuje kratek postopek PCI.
The primary metabolite resulting from the cleavage of Arg3-Pro4 bond of the Nterminal sequence by thrombin is not active because of the loss of affinity to the catalytic active site of thrombin. 
Osnovni presnovek, ki nastane kot posledica cepitve vezi Arg3-Pro4 N-terminalnega zaporedja s trombinom ni aktiven zaradi izgube afinitete do katalitično aktivnega mesta trombina.
• Thrombosis (blood clot) is an uncommon side effect (may affect up to 1 in 100 people) which may result in serious or fatal complications such as heart attack. 
• Tromboza (krvni strdek), občasen neželen učinek (pojavi se lahko pri največ 1 od 100 bolnikov), ki ima lahko za posledice resne zaplete, kakršen je srčni infarkt.
Single bolus doses of bivalirudin up to 7.5 mg/kg have also been reported. 
Poročali so tudi o enkratnih bolusnih odmerkih z do 7,5 mg/kg bivalirudina.
The solution should be a clear to slightly opalescent, colourless to slightly yellow solution. 
Raztopina bi morala biti bistra do rahlo svetlikajoča, brezbarvna do rahlo rumena.
For patients starting with percutaneous coronary intervention (PCI) the recommended dose is: 
Za bolnike, ki začenjajo s perkutano koronarno intervencijo (PCI) je priporočeni odmerek:
Angiox contains bivalirudin, a direct and specific thrombin inhibitor that binds both to the catalytic site and the anion-binding exosite of fluid-phase and clot-bound thrombin. 
Zdravilo Angiox vsebuje bivalirudin, neposreden in specifičen trombinski inhibitor, ki se veže tako na katalitično mesto kot na anionsko zunanje vezavno mesto prostega in na strdek vezanega trombina.
Increased awareness due to high bleeding risk should be exercised in the elderly because of age-related decrease in renal function. 
Pri starejši populaciji je potrebno biti pozoren zaradi tveganja za povečano krvavitev zaradi s starostjo povezanega slabšega delovanja ledvic.
Patients must be observed carefully for symptoms and signs of bleeding during treatment particularly if bivalirudin is combined with another anticoagulant (see section 4.5). 
Med zdravljenjem bodite pozorni na simptome in znake krvavitve pri bolnikih, še posebej, če bivalirudin kombinirate z drugim antikoagulacijskim zdravilom (glejte poglavje 4.5).
INR increased d 
Povečan INR
• a known hypersensitivity to the active substance or to any of the excipients listed in section 6.1, 
• znano preobčutljivostjo na bivalirudin, katerokoli pomožno snov, navedeno v poglavju 6.1, ali
Based on the short half-life of bivalirudin (25 minutes), failure to initiate an infusion following the Angiox bolus will result in a plasma concentration that is below the required level within minutes 
Zaradi kratkega razpolovnega časa bivalirudina (25 minut) lahko izpustitev infuzije, po bolusu zdravila Angiox, v nekaj minutah povzroči plazemske koncentracije, ki so pod zahtevano ravnjo.
Data from 366 patients indicates that the ACT is unaffected by concomitant treatment with a GP IIb/IIIa inhibitor. 
Podatki 366 bolnikov kažejo, da sočasno zdravljenje z zaviralcem GP IIb/IIIa ne vpliva na ACT.
• In patients receiving warfarin, INR is increased by administration of bivalirudin. 
• Pri bolnikih, ki prejemajo varfarin, se z uporabo bivalirudina INR poveča.
Angiox is for injection, followed by infusion (drip), into a vein (never into a muscle). 
Zdravilo Angiox je namenjeno injiciranju, ki mu sledi infundiranje (kapljično) v veno (nikoli v mišico).
The ACT value is positively correlated with the dose and plasma concentration of bivalirudin administered. 
Vrednost ACT je v pozitivni povezavi z odmerkom in koncentracijo danega bivalirudina.